Unmet Needs and Future Perspectives in NSCLC Treatment

As part of a Satellite Sessions program focused on the Cleveland Clinic and surrounding institutions, CancerNetwork hosted a panel discussion on treatment options for patients with EGFR-mutated NSCLC.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

The Oncology Brothers spoke with Benjamin P. Levy, MD, regarding treatment updates for patients with NSCLC with HER2 expression.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Results from the SKIPPirr trial assessed the use of amivantamab plus lazertinib for patients with non–small cell lung cancer.

Taletrectinib demonstrated favorable efficacy and tolerability data in the TRUST-I and TRUST-II trials for the treatment of patients with advanced non–small cell lung cancer.